American Journal of Psychiatry

Objective: Over the past three decades, there have been significant changes in the diagnostic criteria for schizophrenia as well as changes in measurement of IQ. The last quantitative review of the literature on premorbid IQ in schizophrenia ...

https://doi.org/10.1176/appi.ajp.2008.07081242

pdf

abstract

full text

SAVE ARTICLE

Article

Cost-Effectiveness of Treatments for Adolescent Depression: Results From TADS

Publication date: 01 May 2008

Pages588–596

Objective: While the evidence base for treatments for adolescent depression is building, little is known about the relative efficiency of such treatments. Treatment costs are a relevant concern given the competing demands on family and health ...

https://doi.org/10.1176/appi.ajp.2008.07101610

Stimulant Therapy and Risk for Subsequent Substance Use Disorders in Male Adults With ADHD: A Naturalistic Controlled 10-Year Follow-Up Study

Publication date: 01 May 2008

Pages597–603

Objective: The extant literature does not provide definite answers pertaining to whether stimulant treatment increases, decreases, or does not affect the risk for subsequent substance use disorders in youths with attention deficit hyperactivity ...

https://doi.org/10.1176/appi.ajp.2007.07091486

Age of Methylphenidate Treatment Initiation in Children With ADHD and Later Substance Abuse: Prospective Follow-Up Into Adulthood

Publication date: 01 May 2008

Pages604–609

Objective: Animal studies have shown that age at stimulant exposure is positively related to later drug sensitivity. The purpose of this study was to examine whether age at initiation of stimulant treatment in children with attention deficit ...

https://doi.org/10.1176/appi.ajp.2008.07091465

Association of the Neurotrophic Tyrosine Kinase Receptor 3 ( NTRK3 ) Gene and Childhood-Onset Mood Disorders

Publication date: 01 May 2008

Pages610–616

Objective: Genome scans have revealed significant evidence for linkage of depression to chromosome 15q25.3-q26.2. The gene for neurotrophic tyrosine kinase receptor 3 ( NTRK3 ), the receptor for neurotrophin-3 (trkC) and a ...

https://doi.org/10.1176/appi.ajp.2007.07050805

A 6-Week Randomized, Placebo-Controlled Trial of CP-316,311 (a Selective CRH ₁ Antagonist) in the Treatment of Major Depression

Publication date: 01 May 2008

Pages617–620

Objective: The corticotropin-releasing hormone (CRH) system is implicated in the pathogenesis of several psychiatric disorders, including major depressive disorder. This study was designed to evaluate the safety and efficacy of CP-316,311, a ...

https://doi.org/10.1176/appi.ajp.2008.07071199

A Randomized, Controlled Trial of Cognitive-Behavioral Therapy for Augmenting Pharmacotherapy in Obsessive-Compulsive Disorder

Publication date: 01 May 2008

Pages621–630

Objective: Although serotonin reuptake inhibitors (SRIs) are approved for the treatment of obsessive-compulsive disorder (OCD), most OCD patients who have received an adequate SRI trial continue to have clinically significant OCD symptoms. The ...

https://doi.org/10.1176/appi.ajp.2007.07091440

8-Year Follow-Up of Patients Treated for Borderline Personality Disorder: Mentalization-Based Treatment Versus Treatment as Usual

Publication date: 01 May 2008

Pages631–638

Objective: This study evaluated the effect of mentalization-based treatment by partial hospitalization compared to treatment as usual for borderline personality disorder 8 years after entry into a randomized, controlled trial and 5 years after ...

https://doi.org/10.1176/appi.ajp.2007.07040636

The Other-Race Effect in Face Processing Among African American and Caucasian Individuals With Schizophrenia

Publication date: 01 May 2008

Pages639–645

Objective: Studies of emotion recognition abilities in schizophrenia show greater impairment for non-Caucasians with schizophrenia compared with Caucasians. These studies, however, included only Caucasian faces as stimuli. There is evidence ...

https://doi.org/10.1176/appi.ajp.2007.07101604